| Literature DB >> 28904345 |
Prasanna Jagannathan1,2, Fredrick Lutwama3,4, Michelle J Boyle5,6, Felistas Nankya7, Lila A Farrington5, Tara I McIntyre5, Katherine Bowen5, Kate Naluwu7, Mayimuna Nalubega7, Kenneth Musinguzi7, Esther Sikyomu7, Rachel Budker5, Agaba Katureebe7, John Rek7, Bryan Greenhouse5, Grant Dorsey5, Moses R Kamya4, Margaret E Feeney8,9.
Abstract
Vδ2+ γδ T cells are semi-innate T cells that expand markedly following P. falciparum (Pf) infection in naïve adults, but are lost and become dysfunctional among children repeatedly exposed to malaria. The role of these cells in mediating clinical immunity (i.e. protection against symptoms) to malaria remains unclear. We measured Vδ2+ T cell absolute counts at acute and convalescent malaria timepoints (n = 43), and Vδ2+ counts, cellular phenotype, and cytokine production following in vitro stimulation at asymptomatic visits (n = 377), among children aged 6 months to 10 years living in Uganda. Increasing age was associated with diminished in vivo expansion following malaria, and lower Vδ2 absolute counts overall, among children living in a high transmission setting. Microscopic parasitemia and expression of the immunoregulatory markers Tim-3 and CD57 were associated with diminished Vδ2+ T cell pro-inflammatory cytokine production. Higher Vδ2 pro-inflammatory cytokine production was associated with protection from subsequent Pf infection, but also with an increased odds of symptoms once infected. Vδ2+ T cells may play a role in preventing malaria infection in children living in endemic settings; progressive loss and dysfunction of these cells may represent a disease tolerance mechanism that contributes to the development of clinical immunity to malaria.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28904345 PMCID: PMC5597587 DOI: 10.1038/s41598-017-10624-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Age associated differences in probability of symptoms if infected and malaria-associated in vivo Vδ2+ T cell expansion among children in high transmission setting. (A) Increasing parasite prevalence, but lower probability of symptoms given patent infection with increasing age among children in Nagongera, Uganda. Point estimates and 95% confidence intervals derived using multilevel mixed effects logistic regression modeling. (B) Absolute Vδ2 T cell counts at time of malaria and 3, 6, and 9 weeks post-malaria (n = 43, Wilcoxon matched pairs signed-rank). (C) Absolute Vδ2 T cell counts during and after acute malaria episode, stratified by age (0- < 4 yrs, n = 13; 4- < 7 yrs, n = 16; 7–11 yrs, n = 14). Point estimates derived from repeated measures analysis using generalized estimating equations, controlling for Day 0 parasite density.
Figure 2Vδ2+ T cell counts decline with increasing age among children living in high transmission setting. (A) Absolute CD3+Vδ2+ cells/μl among asymptomatic children aged 6 months to 11 years in high (Nagongera) vs low (Walukuba) transmission setting at the time of routine assesments, Wilcoxon Rank Sum. (B) Absolute CD3+ Vδ2+ cells/μl by age in Nagongera. Rs: Spearman Rho. Solid line represents best fit regression line and dashed line represents 95% CI.
Figure 3Concurrent microscopic parasitemia associated with diminished Vδ2+ T cell counts and cytokine production following in vitro stimulation. (A) Absolute CD3+ Vδ2+ cells/μl among uninfected, submicroscopically infected, microscopically infected/asymptomatic, and microscopically infected/symptomatic children living in high transmission setting. (B) Association between absolute CD3+ Vδ2+ cells/μl and parasite densities among infected children (submicroscopically infected children have parasite density estimated at 10 parasites/μl). Shown is 95% confidence interval of best fit regression line. (C) Percentage of Vδ2+ cells among total CD3+ and (D) Percentage of Vδ2+ T cells producing cytokines following in vitro stimulation with P. Falciparum infected red blood cells among uninfected, submicroscopically infected, and microscopically infected/asymptomatic children living in high transmission setting. Rs: Spearman correlation. Between group comparisons made with Wilcoxon ranksum test. Median indicated by black bar.
Figure 4Vδ2+ T cell expression of markers of exhaustion and replicative senescence correlate with loss of effector functions. Vδ2 expression of CD57 (A) and Tim-3 (B) on freshly isolated PBMCs among asymptomatic children compared between children living in high (Nagongera, n = 80) vs low (Walukuba, n = 54) transmission settings. Both CD57 (B) and Tim-3 (C) expression associated with reduced Vδ2+ T cell cytokine production following in vitro stimulation. In high transmission setting, CD57 expression on Vδ2+ T cells associated with increasing age (E); Tim-3 expression associated with infection status at the time of measurement (F). Rs: Spearman correlation. Between group comparisons made with Wilcoxon ranksum.
Vδ2 frequency, functional strata and protection from P. falciparum infection in subsequent year
| Predictora | N (%) | Prevalence of any infection (n/N, %) | Unadjustedb | Adjustedc | ||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | p-value | aOR | 95% CI | p-value | |||
|
| ||||||||
| Low (0.06–0.38) | 93 (35.1) | 300/346, 88% | Ref | Ref | Ref | Ref | Ref | Ref |
| Middle (0.38–0.87) | 92 (34.7) | 258/340, 76% | 0.44 | 0.26–0.75 | 0.002 | 0.49 | 0.30–0.82 | 0.007 |
| High (0.88–8.7) | 80 (30.2) | 215/303, 71% | 0.34 | 0.20–0.59 | <0.001 | 0.35 | 0.21–0.59 | <0.001 |
|
| ||||||||
| Low (0.84–27.8) | 95 (35.9) | 298/350, 85% | Ref | Ref | Ref | Ref | Ref | Ref |
| Middle (28.2–40.3) | 91 (34.3) | 254/339, 75% | 0.44 | 0.26–0.76 | 0.003 | 0.49 | 0.29–0.83 | 0.008 |
| High (40.6–67.0) | 79 (29.8) | 221/300, 74% | 0.41 | 0.24–0.72 | 0.002 | 0.47 | 0.27–0.81 | 0.007 |
|
| ||||||||
| 0 - < 4 | 80 (30.2) | 217/309, 70% | Ref | Ref | Ref | Ref | Ref | Ref |
| ≥4 - < 7 | 87 (32.8) | 272/336, 81% | 2.00 | 1.19–3.38 | 0.009 | 1.64 | 0.99–2.73 | 0.055 |
| ≥7 - < 11 | 98 (37.0) | 284/344, 83% | 2.08 | 1.23–3.51 | 0.006 | 1.79 | 1.08–2.98 | 0.025 |
|
| ||||||||
| 1 - < 8 | 18 (6.8) | 43/66, 65% | Ref | Ref | Ref | Ref | Ref | Ref |
| ≥8 - < 40 | 193 (72.8) | 564/724, 78% | 2.12 | 0.86–5.24 | 0.102 | 2.40 | 1.04–5.56 | 0.04 |
| ≥40–80 | 40 (15.1) | 122/150, 81% | 2.67 | 0.93–7.64 | 0.067 | 3.58 | 1.34–9.53 | 0.011 |
| ≥80 | 14 (5.3) | 44/49, 90% | 6.22 | 1.26–30.63 | 0.025 | 8.60 | 1.96–37.64 | 0.004 |
OR: odds ratio; aOR: adjusted odds ratio
aIncludes n = 265.
bFor analysis, all routine visits were considered. Odds of any infection at routine visits includes both submicroscopic and microscopic infections.
cAdjusted for age category and mosquito exposure rate.
Vδ2 functional strata and odds of symptoms if P. falciparum infected by microscopy in subsequent year
| Predictor | N(%) | Symptoms if infected (n/N, %) | Unadjusted | Adjustedc | ||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | p-value | aOR | 95% CI | p-value | |||
|
| ||||||||
| Low (0.84–27.8) | 95 (35.9) | 73/189, 38% | Ref | Ref | Ref | Ref | Ref | Ref |
| Middle (28.2–40.3) | 91 (34.3) | 91/148, 61% | 3.69 | 1.77–7.69 | <0.001 | 2.73 | 1.39–5.36 | 0.003 |
| High (40.6–67.0) | 79 (29.8) | 69/122, 57% | 3.08 | 1.42–6.67 | 0.004 | 2.27 | 1.11–4.64 | 0.025 |
|
| ||||||||
| 0 - < 4 | 80 (30.2) | 97/138, 70% | Ref | Ref | Ref | Ref | Ref | Ref |
| ≥4 - < 7 | 87 (32.8) | 85/176, 48% | 0.30 | 0.15–0.60 | 0.001 | 0.35 | 0.18–0.70 | 0.003 |
| ≥7 - < 11 | 98 (37.0) | 51/145, 35% | 0.14 | 0.07–0.30 | <0.001 | 0.17 | 0.16–0.47 | <0.001 |
OR: odds ratio; aOR: adjusted odds ratio.
aIncludes n = 225.
bFor analysis, only routine quarterly visits with microscopic infection were considered. Symptomatic malaria considered if blood smear positive and fever at visit, or within 21 days prior and 7 days following visit.
cAdjusted for age category.
Figure 5Children with fewer pro-inflammatory cytokine-producing Vδ2+ T cells are more likely to have asymptomatic infection. Percentage of Vδ2+ T cells producing cytokines following P. falciparum stimulation in children with only symptomatic vs. only asymptomatic infection in year following assay.